Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056489 | 0.78 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDSMN1; SMN2UBE2N | |
| SCHEMBL10967156 | 0.69 | LMNA (0.62) | ALDH1A1KDM4EBACE1PTGS2NPC1 | |
| SCHEMBL21667786 | 0.65 | CA4 (0.62) | ALDH1A1KDM4EBACE1NPC1RAB9A | |
| SCHEMBL31315629 | 0.65 | MAOB (0.56) | ALDH1A1KDM4EHPGDSMN1; SMN2PTGS2 | |
| SCHEMBL3666080 | 0.64 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDSMN1; SMN2UBE2N | |
| SCHEMBL3668412 | 0.64 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDSMN1; SMN2UBE2N | |
| SCHEMBL3049945 | 0.64 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDSMN1; SMN2UBE2N | |
| SCHEMBL21667800 | 0.63 | CA4 (0.59) | ALDH1A1KDM4EBACE1NPC1RAB9A | |
| SCHEMBL21667799 | 0.63 | CA4 (0.59) | ALDH1A1KDM4ESMN1; SMN2BACE1NPC1 | |
| SCHEMBL16672197 | 0.63 | CA4 (0.59) | ALDH1A1KDM4ESMN1; SMN2BACE1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | LAMPE THOMAS | 2010-10-14 | — | — | US | disclosed |
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | LAMPE THOMAS | 2010-10-14 | — | — | US | disclosed |
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | LAMPE THOMAS | 2010-10-14 | — | — | US | disclosed |
| EP-2167482-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer Schering Pharma AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008155017-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155017-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | HMGCR, PCSK9, FABP3 | ALDH1A1 1360/4885KDM4E 3917/4885HPGD 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.